Deutsche Bank Ag\ Prometheus Biosciences, Inc. Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $35.6 Million - $43.5 Million	344,368 Added 2006.11%	361,534 $38.8 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $120,079 - $390,309	3,330 Added 24.07%	17,166 $1.89 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $39,607 - $82,968	-1,406 Reduced 9.22%	13,836 $816,000
Q2 2022 Aug 11, 2022	SELL	$22.39 - $38.94 $28,703 - $49,921	-1,282 Reduced 7.76%	15,242 $430,000
Q1 2022 May 13, 2022	SELL	$30.13 - $50.0 $50,919 - $84,500	-1,690 Reduced 9.28%	16,524 $624,000

Q4 2021 Feb 11, 2022	BUY	$22.28 - $39.54 $260,987 - $463,171	11,714 Added 180.22%	18,214 $720,000
Q3 2021 Nov 04, 2021	SELL	$20.89 - $26.96 $4,366 - $5,634	-209 Reduced 3.12%	6,500 $154,000
Q2 2021 Aug 11, 2021	BUY	$16.8 - $29.65 $112,711 - $198,921	6,709 New	6,709 $165,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.